Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Gilead Diversifies Pharmaceutical Marketing Strategy for HIV Drug

XTALKS VITALS NEWS

Pharmaceutical Marketing

The announcement was made during a call with investors last week, with Gilead’s EVP of worldwide commercial operations, James Myers, commenting that the marketing campaign will be aimed at boosting awareness in traditionally underserved populations.

Share this!

February 14, 2017 | by Sarah Hand, M.Sc.

According to an article published in MM&M, biopharma company Gilead Sciences will use some unconventional platforms – including Tumblr, Snapchat and dating sites – as part of their pharmaceutical marketing strategy for their HIV preventative treatment, Truvada. The announcement was made during a call with investors last week, with Gilead’s EVP of worldwide commercial operations, James Myers, commenting that the marketing campaign will be aimed at boosting awareness in traditionally underserved populations.

According to Myers, awareness of Truvada and its use as a pre-exposure prophylaxis (PrEP) against HIV, is high in some large cities like San Francisco, but much lower in others. In particular, he explains that those in inner city areas are most at risk of contracting HIV, and that social platforms may be the best way to reach these individuals.

Specifically, Gilead aims to raise awareness of Truvada in cities including New Orleans, Baltimore, Washington D.C., Oakland, and Newark. The HIV rate in San Francisco has been slowly on the decline, with officials naming Truvada as one of the contributing factors.

“There is an opportunity to replicate this success in other areas across the United States, and Gilead has been encouraged to play a more prominent role in PrEP education and has done so via the hiring of a field-based team,” said Kevin Young, Gilead's COO. While awareness could go a long way to reducing the rate of infection across the country, Gilead’s other hurdle is getting payers to cover the cost of the preventive therapy.



For uninsured individuals, Truvada costs approximately $1,300 per month, however this is often less expensive than treating patient infected with HIV in the long-term. “If we can prevent HIV from occurring, ultimately that's going to bring down costs of treatment – and that's a lifetime cost of treatment,” said Meyers.

While some are confident in the drug’s potential to lower HIV infection rates, others have expressed concerns that the prophylactic could encourage risky sexual behavior. The AIDS Healthcare Foundation – an LA-based patient advocacy group – have said that people taking the drug may decide to stop using condoms, thereby increasing their risk of contracting other STIs.

Truvada was approved by the US Food and Drug Administration (FDA) in 2012, with a reported 110,000 people taking the PrEP at the end of last year. The drug – which uses a combination of emtricitabine and tenofovir – is also used to treat patients with HIV.


Keywords: Pharmaceutical Marketing, HIV, Drug Awareness


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
New Self-Injectable Form of Lupus Drug Approved by the FDA

July 25, 2017 - Patients with systemic lupus erythematosus (SLE) will now have the option to self-inject their medication thanks to the FDA approval of GSK’s reformulated lupus drug, Benlysta (belimumab).

Featured In: Biotech News


Canadian Chicken Farmers to Further Reduce Use of Antibiotics

July 24, 2017 - The Chicken Farmers of Canada, a national group dedicated to supporting poultry farmers and helping them meet consumer demand for chicken, has announced their strategy for eliminating the use of certain antimicrobials in meat production.

Featured In: Food News


Neonatal MRI Medical Device Approved by the FDA

July 24, 2017 - Medical device maker Aspect Imaging has received US Food and Drug Administration (FDA) approval for its Embrace Neonatal MRI System.

Featured In: Medical Device News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Manufacturing Control Strategies: What Pharmaceutical and Biotech Companies Need to Know

REGISTER FOR THESE WEBINARS

Outsourcing Pharmacovigilance: Pros and Cons and Lessons Learned


EDC and eSource: Combined for Better Data and Faster Insights


Using Model Reduction to Bridge the Quality Systems Pharmacology-Pharmacometrics Divide


How to Maximize Your Non-GLP Toxicology Studies: A Guide for Optimal Design and Methodology


Copyright © 2016-2017 Honeycomb Worldwide Inc.